Bioavailability & Bioequivalence studies of Biopharmaceuticals

The assessment of BA/BE of different drug products is based on the fundamental assumption that two products are equivalent when the rate and extent of absorption of the test drug does not show a significant difference from the rate and extent of absorption of the reference drug when administered at the same molar dose of the therapeutic ingredient under similar experimental conditions in either a single dose or multiple doses. Should the rate of absorption actually differ between products, it would have to be intentional and reflected in the proposed product label and be clearly demonstrated that it is not essential in the attainment of effective body drug concentrations on chronic use or has been shown to be medically insignificant for the drug. In practice, equivalence is indicated when key pharmacokinetic parameters used to establish rate and extent of the test, and reference products fall within a present confidence interval. The FDA declares a drug product to be therapeutically equivalent to the innovator product if it is pharmaceutically equivalent, i.e., same active ingredient, dosage form, strength and route of administration, and bioequivalent. Products that are therapeutically equivalent can be used interchangeably. Thus, BE studies are construed to be considered surrogates for comparative clinical trials for the assessment of therapeutic equivalence in safety and efficacy between two drug products.

  • Drug Absorption and Distribution
  • Bioequivalence Protocols : In vitro-In vivo correlation
  • Dissolution Studies
  • PK/PD studies

Related Conference of Bioavailability & Bioequivalence studies of Biopharmaceuticals

August 18-19, 2025

40th World Congress on Pharmacology and Therapeutics

Valencia, Spain
August 27-28, 2025

20th World Congress on Drug Formulation & Drug Delivery

Amsterdam, Netherlands
September 19-20, 2025

18th World Drug Delivery Summit

Paris, France
September 22-23, 2025

Pharma Biotech Expo

Toronto, Canada
September 23-24, 2025

10th International Conference on Future Pharma and Innovations

Amsterdam, Netherlands
September 24-25, 2025

5th World Congress on Rare Diseases & Orphan Drugs

Aix-en-Provence, France
October 23-24, 2025

21st Annual Meet on Pharmaceutical Sciences

Aix-en-Provence, France
November 11-12, 2025

6th Annual Congress on Antibiotics and Bacterial Infections

Amsterdam, Netherlands
November 13-14, 2025

21st International Conference on Pharmaceutical Chemistry

Aix-en-Provence, France
November 20-21, 2025

21st Annual Congress on Pharmacology and Toxicology

Paris, France
November 27-28, 2025

4th World Congress on Precision and Personalized Medicine

Zurich, Switzerland
November 27-28, 2025

4th World Conference on Pharma Industry and Medical Devices

Zurich, Switzerland
November 27-28, 2025

13th International Conference on Clinical Trials

Amsterdam, Netherlands
February 23-24, 2026

3rd World Congress on Biologics and Biosimilars

London, Aland Islands
April 27-28, 2026

9th European Biopharma Congress

Paris, Aland Islands

Bioavailability & Bioequivalence studies of Biopharmaceuticals Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in